ARA-290 vs Dermorphin
A side-by-side research comparison of ARA-290 and Dermorphin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ARA-290 | Dermorphin |
|---|---|---|
| Full name | Cibinetide (ARA-290) | Dermorphin (Opioid Heptapeptide) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Investigational | Research compound |
| Mechanism | Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation. | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. |
| Molecular weight | ~1257 Da | 803.9 Da |
| Half-life | Short (minutes in plasma); effects outlast plasma levels | Short (peptide) |
| Bioavailability | High via subcutaneous injection | Injection (research) |
| Typical dose | 1-4 mg per dose | Not established for human use |
| Frequency | Daily during a course | Research only |
| Route | Subcutaneous injection | Injection (research) |
ARA-290 reported benefits
- Reduces neuropathic pain
- Anti-inflammatory tissue protection
- Supports small-fiber nerve repair
- No increase in red blood cell mass (unlike EPO)
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
Related comparisons
Research and educational reference only. Not medical advice.